Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Formiga F
  • Rubio-Rivas M
  • Mora-Luján JM
  • Escudero SC
  • Martinez RFM
  • Mendez-Bailón M
  • Campo PD
  • Pérez AR
  • García-Sánchez FJ
  • Alcalá-Pedrajas JN
  • Hernández SA
  • Milian AH
  • Díez AL
  • Boixeda R
  • Vicente J
  • Cortes B
  • Pérez CM
  • Espartero MEG
  • Castro JL
  • Suárez SR
  • Varona JF
  • Gomez-Huelgas R
  • Ramos-Rincón JM
  • SEMI-COVID-19 SEMI-COVID-19 Network

Grupos

Abstract

Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.

© 2021. Società Italiana di Medicina Interna (SIMI).

Datos de la publicación

ISSN/ISSNe:
1828-0447, 1970-9366

INTERNAL AND EMERGENCY MEDICINE  SPRINGER-VERLAG ITALIA SRL

Tipo:
Article
Páginas:
1-15
Factor de Impacto:
0,861 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acetylsalicylic acid; COVID-19; Coronavirus; Mortality

Campos de estudio

Cita

Compartir